Effect of ACE inhibitors on angiographic restenosis after coronary stenting (PARIS): a randomised, double-blind, placebo-controlled trial
- 1 April 2001
- journal article
- clinical trial
- Published by Elsevier in The Lancet
- Vol. 357 (9265) , 1321-1324
- https://doi.org/10.1016/s0140-6736(00)04518-9
Abstract
No abstract availableKeywords
This publication has 18 references indexed in Scilit:
- Six-Month Angiographic Outcome After Successful Repeat Percutaneous Intervention for In-Stent RestenosisCirculation, 1998
- Plasma Activity and Insertion/Deletion Polymorphism of Angiotensin I–Converting EnzymeCirculation, 1998
- D Allele of the Angiotensin I–Converting Enzyme Is a Major Risk Factor for Restenosis After Coronary StentingCirculation, 1997
- Patterns and Mechanisms of In-Stent RestenosisCirculation, 1996
- Arterial Remodeling After Coronary AngioplastyCirculation, 1996
- A Randomized Comparison of Coronary-Stent Placement and Balloon Angioplasty in the Treatment of Coronary Artery DiseaseNew England Journal of Medicine, 1994
- Does the new angiotensin converting enzyme inhibitor cilazapril prevent restenosis after percutaneous transluminal coronary angioplasty? Results of the MERCATOR study: a multicenter, randomized, double-blind placebo-controlled trial. Multicenter European Research Trial with Cilazapril after Angioplasty to Prevent Transluminal Coronary Obstruction and Restenosis (MERCATOR) Study Group.Circulation, 1992
- Angiographic Follow-up after Placement of a Self-Expanding Coronary-Artery StentNew England Journal of Medicine, 1991
- An insertion/deletion polymorphism in the angiotensin I-converting enzyme gene accounting for half the variance of serum enzyme levels.Journal of Clinical Investigation, 1990
- Inhibitors of Angiotensin-Converting Enzyme Prevent Myointimal Proliferation After Vascular InjuryScience, 1989